Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence

Mohammed E. Al-Sofiani, Robert Derenbecker, Michael Quartuccio, Rita R. Kalyani

Research output: Contribution to journalReview article

Abstract

Purpose of Review: People with diabetes are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) compared with those without diabetes. Though aspirin has been shown to have an overall net clinical benefit when used for secondary prevention of ASCVD in people with and without diabetes, the evidence for primary prevention, especially in those with diabetes, remains inconsistent. In this article, we review the latest studies examining the risks and benefits of aspirin use for primary prevention of ASCVD in adults with diabetes, discuss key aspects in assessing the risk-benefit ratio of aspirin use for primary prevention of ASCVD, and summarize current guidelines from professional societies on aspirin use for primary prevention in adults with diabetes. Recent Findings: In the general population, past studies have shown no difference in the beneficial effect of aspirin for primary cardiovascular disease prevention by diabetes status. However, several randomized controlled studies and meta-analyses in adults with diabetes have shown lack of net clinical benefit of aspirin use for primary prevention of ASCVD. The recent ASCEND trial documented cardiovascular benefit of aspirin for primary prevention in adults with diabetes but suggested that the increased risk of bleeding may outweigh the cardiovascular benefit. Summary: The decision to initiate aspirin for primary prevention of ASCVD must be considered carefully on an individual basis to balance the cardiovascular benefit and bleeding risk in all patients, especially those with diabetes. A multifactorial approach that focuses on managing ASCVD risk factors such as hypertension, dyslipidemia, dysglycemia, and smoking is recommended in all patients. More research is needed to identify subgroups of people with diabetes who are more likely to benefit from aspirin use for primary prevention of ASCVD and develop better antithrombotic strategies that shift the risk-benefit balance toward an overall net clinical benefit.

Original languageEnglish (US)
Article number107
JournalCurrent Diabetes Reports
Volume19
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Primary Prevention
Aspirin
Cardiovascular Diseases
Hemorrhage
Dyslipidemias
Secondary Prevention
Meta-Analysis
Smoking
Odds Ratio
Guidelines
Hypertension
Research

Keywords

  • Aspirin
  • Atherosclerotic cardiovascular disease
  • Diabetes
  • Primary cardiovascular prevention

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes : a Review of the Evidence. / Al-Sofiani, Mohammed E.; Derenbecker, Robert; Quartuccio, Michael; Kalyani, Rita R.

In: Current Diabetes Reports, Vol. 19, No. 10, 107, 01.10.2019.

Research output: Contribution to journalReview article

Al-Sofiani, Mohammed E. ; Derenbecker, Robert ; Quartuccio, Michael ; Kalyani, Rita R. / Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes : a Review of the Evidence. In: Current Diabetes Reports. 2019 ; Vol. 19, No. 10.
@article{dc61d05d70fc4800bc19e6ac69baafdf,
title = "Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence",
abstract = "Purpose of Review: People with diabetes are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) compared with those without diabetes. Though aspirin has been shown to have an overall net clinical benefit when used for secondary prevention of ASCVD in people with and without diabetes, the evidence for primary prevention, especially in those with diabetes, remains inconsistent. In this article, we review the latest studies examining the risks and benefits of aspirin use for primary prevention of ASCVD in adults with diabetes, discuss key aspects in assessing the risk-benefit ratio of aspirin use for primary prevention of ASCVD, and summarize current guidelines from professional societies on aspirin use for primary prevention in adults with diabetes. Recent Findings: In the general population, past studies have shown no difference in the beneficial effect of aspirin for primary cardiovascular disease prevention by diabetes status. However, several randomized controlled studies and meta-analyses in adults with diabetes have shown lack of net clinical benefit of aspirin use for primary prevention of ASCVD. The recent ASCEND trial documented cardiovascular benefit of aspirin for primary prevention in adults with diabetes but suggested that the increased risk of bleeding may outweigh the cardiovascular benefit. Summary: The decision to initiate aspirin for primary prevention of ASCVD must be considered carefully on an individual basis to balance the cardiovascular benefit and bleeding risk in all patients, especially those with diabetes. A multifactorial approach that focuses on managing ASCVD risk factors such as hypertension, dyslipidemia, dysglycemia, and smoking is recommended in all patients. More research is needed to identify subgroups of people with diabetes who are more likely to benefit from aspirin use for primary prevention of ASCVD and develop better antithrombotic strategies that shift the risk-benefit balance toward an overall net clinical benefit.",
keywords = "Aspirin, Atherosclerotic cardiovascular disease, Diabetes, Primary cardiovascular prevention",
author = "Al-Sofiani, {Mohammed E.} and Robert Derenbecker and Michael Quartuccio and Kalyani, {Rita R.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1007/s11892-019-1206-6",
language = "English (US)",
volume = "19",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "10",

}

TY - JOUR

T1 - Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes

T2 - a Review of the Evidence

AU - Al-Sofiani, Mohammed E.

AU - Derenbecker, Robert

AU - Quartuccio, Michael

AU - Kalyani, Rita R.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Purpose of Review: People with diabetes are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) compared with those without diabetes. Though aspirin has been shown to have an overall net clinical benefit when used for secondary prevention of ASCVD in people with and without diabetes, the evidence for primary prevention, especially in those with diabetes, remains inconsistent. In this article, we review the latest studies examining the risks and benefits of aspirin use for primary prevention of ASCVD in adults with diabetes, discuss key aspects in assessing the risk-benefit ratio of aspirin use for primary prevention of ASCVD, and summarize current guidelines from professional societies on aspirin use for primary prevention in adults with diabetes. Recent Findings: In the general population, past studies have shown no difference in the beneficial effect of aspirin for primary cardiovascular disease prevention by diabetes status. However, several randomized controlled studies and meta-analyses in adults with diabetes have shown lack of net clinical benefit of aspirin use for primary prevention of ASCVD. The recent ASCEND trial documented cardiovascular benefit of aspirin for primary prevention in adults with diabetes but suggested that the increased risk of bleeding may outweigh the cardiovascular benefit. Summary: The decision to initiate aspirin for primary prevention of ASCVD must be considered carefully on an individual basis to balance the cardiovascular benefit and bleeding risk in all patients, especially those with diabetes. A multifactorial approach that focuses on managing ASCVD risk factors such as hypertension, dyslipidemia, dysglycemia, and smoking is recommended in all patients. More research is needed to identify subgroups of people with diabetes who are more likely to benefit from aspirin use for primary prevention of ASCVD and develop better antithrombotic strategies that shift the risk-benefit balance toward an overall net clinical benefit.

AB - Purpose of Review: People with diabetes are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) compared with those without diabetes. Though aspirin has been shown to have an overall net clinical benefit when used for secondary prevention of ASCVD in people with and without diabetes, the evidence for primary prevention, especially in those with diabetes, remains inconsistent. In this article, we review the latest studies examining the risks and benefits of aspirin use for primary prevention of ASCVD in adults with diabetes, discuss key aspects in assessing the risk-benefit ratio of aspirin use for primary prevention of ASCVD, and summarize current guidelines from professional societies on aspirin use for primary prevention in adults with diabetes. Recent Findings: In the general population, past studies have shown no difference in the beneficial effect of aspirin for primary cardiovascular disease prevention by diabetes status. However, several randomized controlled studies and meta-analyses in adults with diabetes have shown lack of net clinical benefit of aspirin use for primary prevention of ASCVD. The recent ASCEND trial documented cardiovascular benefit of aspirin for primary prevention in adults with diabetes but suggested that the increased risk of bleeding may outweigh the cardiovascular benefit. Summary: The decision to initiate aspirin for primary prevention of ASCVD must be considered carefully on an individual basis to balance the cardiovascular benefit and bleeding risk in all patients, especially those with diabetes. A multifactorial approach that focuses on managing ASCVD risk factors such as hypertension, dyslipidemia, dysglycemia, and smoking is recommended in all patients. More research is needed to identify subgroups of people with diabetes who are more likely to benefit from aspirin use for primary prevention of ASCVD and develop better antithrombotic strategies that shift the risk-benefit balance toward an overall net clinical benefit.

KW - Aspirin

KW - Atherosclerotic cardiovascular disease

KW - Diabetes

KW - Primary cardiovascular prevention

UR - http://www.scopus.com/inward/record.url?scp=85072577414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072577414&partnerID=8YFLogxK

U2 - 10.1007/s11892-019-1206-6

DO - 10.1007/s11892-019-1206-6

M3 - Review article

C2 - 31544224

AN - SCOPUS:85072577414

VL - 19

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 10

M1 - 107

ER -